Citation: Ruiquan Liu, Wenwen Duan, Wenzhong Yan, Jinfeng Zhang, Jianjun Cheng. Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A_2A adenosine receptors and histone deacetylases[J]. Chinese Chemical Letters, ;2024, 35(1): 108136. doi: 10.1016/j.cclet.2023.108136 shu

Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A_2A adenosine receptors and histone deacetylases

Ruiquan Liu ^a ,
Wenwen Duan ^a ,
Wenzhong Yan ^a ,
Jinfeng Zhang ^a ,
Jianjun Cheng ^{a, b, *,}

a.
iHuman Institute, ShanghaiTech University, Shanghai 201210, China
b.
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China

chengjj@shanghaitech.edu.cn

Received Date: 11 October 2022
Revised Date: 3 January 2023
Accepted Date: 4 January 2023
Available Online: 5 January 2023

Figures(5)

The A_2A adenosine receptor (A_2AAR) has attracted attention as an emerging immunotherapeutic target with several antagonists being evaluated in clinical trials. However, A_2AAR antagonists show limited efficacy as monotherapies. Herein, we communicate our design and synthesis of a novel series of A_2AAR/histone deacetylase (HDAC) bifunctional inhibitors, based on the core structure of the A_2AAR antagonist PBF-509. The new compounds were designed using a pharmacophore-merging strategy and features a tri-substituted pyrimidine core. The binding affinity for A_2AAR and inhibitory activity against HDACs of all the new compounds were tested. A number of compounds exhibited nanomolar or subnanomolar activity against both targets and some showed equally potent antiproliferative activity against MC38, CT26 and HCT116 colon cancer lines compared to HDAC inhibitors SAHA and MGCD-0103 in vitro. The binding poses of compound 5a in both A_2AAR and HDAC1 were predicted by molecular docking studies. Collectively, these results suggest these tri-substituted pyrimidine derivatives are promising leads for developing A_2AAR/HDAC dual-acting compounds as novel antitumor agents.
- Bifunctional,
- A_2AAR antagonism,
- HDAC inhibition,
- Cancer,
- Immunotherapy
1. [1]
  J. Blay, T.D. White, D.W. Hoskin, Cancer Res. 57 (1997) 2602–2605.
2. [2]
  D. Vijayan, A. Young, M. Teng, et al., Nat. Rev. Cancer 17 (2017) 709–724. doi: 10.1038/nrc.2017.86
3. [3]
  B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, et al., Pharmacol. Rev. 63 (2017) 1–34. doi: 10.4324/9781315177151-1
4. [4]
  A. Ohta, M. Sitkovsky, Nature 414 (2001) 916–919. doi: 10.1038/414916a
5. [5]
  A. Ohta, E. Gorelik, S.J. Prasad, et al., Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13132–13137. doi: 10.1073/pnas.0605251103
6. [6]
  J. Kjaergaard, S. Hatfield, G. Jones, et al., J. Immunol. 201 (2018) 782–791. doi: 10.4049/jimmunol.1700850
7. [7]
  J. Zhang, W. Yan, W. Duan, et al., Pharmaceuticals 13 (2020) 237. doi: 10.3390/ph13090237
8. [8]
  F. Yu, C. Zhu, Q. Xie, et al., J. Med. Chem. 63 (2020) 12196–12212. doi: 10.1021/acs.jmedchem.0c00237
9. [9]
  A. Anighoro, J. Bajorath, G. Rastelli, et al., J. Med. Chem. 57 (2014) 7874–7887. doi: 10.1021/jm5006463
10. [10]
  Y. Ren, Q. Sun, Z. Yuan, et al., Chin. Chem. Lett. 30 (2019) 1233–1236. doi: 10.1016/j.cclet.2019.03.029
11. [11]
  Q. Sun, Q. Dai, C. Zhang, et al., Chin. Chem. Lett. 32 (2021) 2479–2483. doi: 10.1016/j.cclet.2021.02.004
12. [12]
  X. Cai, H.X. Zhai, J. Wang, et al., J. Med. Chem. 53 (2010) 2000–2009. doi: 10.1021/jm901453q
13. [13]
  C.J. Lai, R. Bao, T. Xu, et al., Cancer Res. 70 (2010) 3647–3656.
14. [14]
  C. Ding, D. Li, Y.W. Wang, et al., Chin. Chem. Lett. 28 (2017) 1220–1227. doi: 10.1016/j.cclet.2017.01.003
15. [15]
  K. Sun, R. Atoyan, M.A. B. orek, et al., Mol. Cancer Ther. 16 (2016) 285–299.
16. [16]
  Y. Huang, S. Chen, S. Wu, et al., Acta Pharm. Sin. B 10 (2020) 1294–1308. doi: 10.1016/j.apsb.2019.11.011
17. [17]
  S. Wu, Y. Huang, T. Wang, et al., J. Med. Chem. 65 (2022) 4818–4831. doi: 10.1021/acs.jmedchem.1c02026
18. [18]
  Y. Huang, G. Dong, H. Li, et al., J. Med. Chem. 61 (2018) 6056–6074. doi: 10.1021/acs.jmedchem.8b00393
19. [19]
  X. Liang, J. Zang, X. Li, et al., J. Med. Chem. 62 (2019) 3898–3923. doi: 10.1021/acs.jmedchem.8b01597
20. [20]
  W. Yan, L. Ling, Y. Wu, et al., J. Med. Chem. 64 (2021) 16573–16597. doi: 10.1021/acs.jmedchem.1c01155
21. [21]
  J. Zhang, Z. Luo, W. Duan, et al., Eur. J. Med. Chem. 236 (2022) 114326. doi: 10.1016/j.ejmech.2022.114326
22. [22]
  A. Borodovsky, C.M. Barbon, Y. Wang, et al., J. ImmunoTher. Cancer 8 (2020) e000417. doi: 10.1136/jitc-2019-000417
23. [23]
  J.A. Camacho Gomez, J.C. Castro-Palomino Laria, Patent, WO2011121418 A1, 2011.
24. [24]
  D.H. Slee, Y. Chen, X. Zhang, et al., J. Med. Chem. 51 (2008) 1719–1729. doi: 10.1021/jm701185v
25. [25]
  D. Slee, M. Lanier, B.G. Vong, et al., Patent, WO2006110884 A2, 2006.
26. [26]
  D. Slee, X. Zhang, J.K. Rueter, et al., Patent, WO2007084914 A2, 2007.
27. [27]
  B. Bernet, P.M. Bishop, M. Caron, et al., Can. J. Chem. 63 (1985) 2818–2820. doi: 10.1139/v85-470
28. [28]
  M. Mediavilla-Varela, J. Castro, A. Chiappori, et al., Neoplasia 19 (2017) 530–536. doi: 10.1016/j.neo.2017.02.004
29. [29]
  P.A. B. eavis, N. Milenkovski, M.A. H. enderson, et al., Cancer Immunol. Res. 5 (2015) 506–517.
30. [30]
  R.D. L. eone, I.M. S. un, M.H. O. h, et al., Cancer Immunol. Immun. 67 (2018) 1271–1284. doi: 10.1007/s00262-018-2186-0
1. [1]
  Xin Li , Xuan Ding , Junkun Zhou , Hui Shi , Zhenxi Dai , Jiayi Liu , Yongcun Ma , Penghui Shao , Liming Yang , Xubiao Luo . Utilizing synergistic effects of bifunctional polymer hydrogel PAM-PAMPS for selective capture of Pb(Ⅱ) from wastewater. Chinese Chemical Letters, 2024, 35(7): 109158-. doi: 10.1016/j.cclet.2023.109158
2. [2]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
3. [3]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
4. [4]
  Hao Cai , Xiaoyan Wu , Lei Jiang , Feng Yu , Yuxiang Yang , Yan Li , Xian Zhang , Jian Liu , Zijian Li , Hong Bi . Lysosome-targeted carbon dots with a light-controlled nitric oxide releasing property for enhanced photodynamic therapy. Chinese Chemical Letters, 2024, 35(4): 108946-. doi: 10.1016/j.cclet.2023.108946
5. [5]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
6. [6]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
7. [7]
  Yuanyi Zhou , Ke Ma , Jinfeng Liu , Zirun Zheng , Bo Hu , Yu Meng , Zhizhong Li , Mingshan Zhu . Is reactive oxygen species the only way for cancer inhibition over single atom nanomedicine? Autophagy regulation also works. Chinese Chemical Letters, 2024, 35(6): 109056-. doi: 10.1016/j.cclet.2023.109056
8. [8]
  Jing Cao , Dezheng Zhang , Bianqing Ren , Ping Song , Weilin Xu . Mn incorporated RuO₂ nanocrystals as an efficient and stable bifunctional electrocatalyst for oxygen evolution reaction and hydrogen evolution reaction in acid and alkaline. Chinese Chemical Letters, 2024, 35(10): 109863-. doi: 10.1016/j.cclet.2024.109863
9. [9]
  Haodong Wang , Xiaoxu Lai , Chi Chen , Pei Shi , Houzhao Wan , Hao Wang , Xingguang Chen , Dan Sun . Novel 2D bifunctional layered rare-earth hydroxides@GO catalyst as a functional interlayer for improved liquid-solid conversion of polysulfides in lithium-sulfur batteries. Chinese Chemical Letters, 2024, 35(5): 108473-. doi: 10.1016/j.cclet.2023.108473
10. [10]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
11. [11]
  Fanxin Kong , Hongzhi Wang , Huimei Duan . Inhibition effect of sulfation on Pt/TiO2 catalysts in methane combustion. Chinese Journal of Structural Chemistry, 2024, 43(5): 100287-100287. doi: 10.1016/j.cjsc.2024.100287
12. [12]
  Huijiao Fu , Peiqin Liang , Qianwen Chen , Yan Wang , Guang Li , Xuzi Cai , Shengtao Wang , Kun Chen , Shengying Shi , Zhiqiang Yu , Xuefeng Wang . COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach. Chinese Chemical Letters, 2024, 35(8): 109241-. doi: 10.1016/j.cclet.2023.109241
13. [13]
  Shuang Li , Jiayu Sun , Guocheng Liu , Shuo Zhang , Zhong Zhang , Xiuli Wang . A new Keggin-type polyoxometallate-based bifunctional catalyst for trace detection and pH-universal photodegradation of phenol. Chinese Chemical Letters, 2024, 35(8): 109148-. doi: 10.1016/j.cclet.2023.109148
14. [14]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
15. [15]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
16. [16]
  Haijing Cui , Weihao Zhu , Chuning Yue , Ming Yang , Wenzhi Ren , Aiguo Wu . Recent progress of ultrasound-responsive titanium dioxide sonosensitizers in cancer treatment. Chinese Chemical Letters, 2024, 35(10): 109727-. doi: 10.1016/j.cclet.2024.109727
17. [17]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
18. [18]
  Xiangqian Cao , Chenkai Yang , Xiaodong Zhu , Mengxin Zhao , Yilin Yan , Zhengnan Huang , Jinming Cai , Jingming Zhuang , Shengzhou Li , Wei Li , Bing Shen . Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM. Chinese Chemical Letters, 2024, 35(8): 109199-. doi: 10.1016/j.cclet.2023.109199
19. [19]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
20. [20]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967

Get Citation

PDF

XML

Metrics

PDF Downloads(18)
Abstract views(296)
HTML views(19)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A2A adenosine receptors and histone deacetylases

Metrics

通讯作者: 陈斌, bchen63@163.com

Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A_2A adenosine receptors and histone deacetylases